CDK4 and neoplasm: However, combinatorial treatment with a CDK4/i and an ERK-MAPK inhibitor synergistically suppresses tumor growth through blocking CDK4/6i-induced compensatory upregulation of ERK, PI3K, antiapoptotic signaling, and MYC expression in PDAC cell lines and organoids[66].